Elmiron (pentosan polysulfate sodium)
- Region
- 🇪🇺 EU
- Active substance
- pentosan polysulfate sodium
- Company
- bene-Arzneimittel GmbH
- Status
- Authorised
- Therapeutic area
- Cystitis, Interstitial
- EU approval
- Fri 02 Jun 2017
- Application
- EMEA/H/C/004246
- ATC
- G04BX15
- Official record
- www.ema.europa.eu
Indication
Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition.
Regulatory milestones
No milestones recorded in the last year.
Follow Elmiron
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.